Watch for downward pressure on APGE shares as the market interprets these sales as negative signaling, especially given the proximity to a large dilutive offering. The fact that both the CFO and CMO sold — not just one-off participants — increases the perceived credibility of the bearish signal. Consider hedging long positions or monitoring for further insider exits.
Price Chart
Executive Summary
Two Apogee Therapeutics insiders — the CFO and CMO — sold a combined $303K in stock within a week of a $350M public offering, suggesting potential insider concern ahead of material dilution. The sales represent informed selling by senior executives just after the company priced its secondary offering above market.
Key Financial Metrics
Key Facts
- CFO Jane Henderson sold $76,014 in shares (900 shares at $84.46) on April 1, 2026
- CMO Carl Dambkowski sold $227,468 in shares (2,698 shares at $84.31) on April 1, 2026
- Total open-market insider sales: $303,482
- Sales occurred 7 days after final pricing of a $350M secondary offering (5M shares at $70.00)
- Offering priced below market ($70 vs $73 closing price on March 24), but insiders sold near post-offering price of $84
- Insiders sold after underwriting agreement was signed and offering terms finalized
Financial Impact
$303K in insider selling, representing 0.005% of $5.9B market cap — modest in size but highly significant due to timing and participants
Risk Factors
- Insiders may have sold for personal liquidity needs unrelated to company outlook
- Stock price had run up post-offering, prompting routine profit-taking
- Exercise-and-sell transaction (by Dambkowski) could be part of a pre-arranged 10b5-1 plan
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-APGE-1775260875343 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 15-12G | — | awaiting T+5 | — | — |
Sep 3, 2026 29d ago | 25-NSE | $135.06 awaiting T+5 | awaiting T+5 | — | — |
Sep 3, 2026 29d ago | 8-K | $135.06 awaiting T+5 | awaiting T+5 | — | — |
Aug 11, 2026 7w ago | 8-K | $134.55 $134.71 | ▲ +0.12% | ▲ +0.56% | — |
Aug 10, 2026 7w ago | 8-K | $134.65 $134.59 | ▼ −0.04% | ▲ +0.00% | — |
Aug 10, 2026 7w ago | Press Release | $134.65 $134.59 | ▼ −0.04% | ▲ +0.00% | — |
Aug 6, 2026 8w ago | Institutional Cluster | $134.49 $134.45 | ▼ −0.03% | ▼ −1.24% | — |
Aug 3, 2026 8w ago | DEFA14A | $134.19 $134.69 | ▲ +0.37% | ▲ +0.47% | — |
Jul 11, 2026 11w ago | Insider Cluster | $133.82 $134.00 | ▲ +0.13% | ▲ +0.92% | — |
Jun 26, 2026 13w ago | DEFA14A | $132.61 $133.50 | ▲ +0.67% | ▼ −0.72% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access